Insiders who reported open-market trades in the last 12 months at the companies Keith R. Leonard files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Gary S. Guthart - $48.79M in ISRG purchases and sales in the last 12 months
David J. Rosa - $13.41M in ISRG purchases and sales in the last 12 months
Myriam Curet - $8.38M in ISRG purchases and sales in the last 12 months
Henry L. Charlton - $7.96M in ISRG purchases and sales in the last 12 months
Todd Watanabe - $4.44M in ARQT purchases and sales in the last 12 months
Mark Brosius - $2.95M in ISRG purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Keith R. Leonard is a corporate insider, tracked as Director of Arcutis Biotherapeutics, Inc. (ARQT). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Keith R. Leonard last file a Form 4?
The most recent primary Form 4 on record is dated 10 June 2026, one of 8 filings going back to 2025.
Has Keith R. Leonard been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($997K) across all tracked filings.
Keith R. Leonard is Director of Arcutis Biotherapeutics, Inc. (ARQT). 8 SEC Form 4 filings on record going back to 2025, most recently on 10 June 2026. Most recent open-market trade: sold $997K of ARQT on 4 March 2026. Lifetime open-market sales: $997K.
Recent transactions
9
The latest 9 SEC Form 4 transactions reported by Keith R. Leonard.
InsiderAlpha's records for Keith R. Leonard go back to 2025: 8 primary Form 4 filings, an average of 4.0 per year. 5 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
